- Home
- BMN vs CGTX Comparison
BMN vs CGTX Comparison
Compare BMN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMN | CGTX |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | 19800 | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.8M | 158.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BMN | CGTX |
|---|---|---|
| Price | $25.25 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 29.9K | ★ 942.9K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.51 | $0.22 |
| 52 Week High | $25.59 | $3.83 |
Technical Indicators
Market Signals| Indicator | BMN | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 50.36 |
| Support Level | $25.11 | $1.69 |
| Resistance Level | $25.42 | $1.76 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 78.41 | 56.72 |
Price Performance
Historical ComparisonAbout BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest
BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.